In a rheumatoid arthritis patient receiving methotrexate and adalimumab who presents with fever, rash, myalgia, and facial pain, what is the appropriate treatment?

Immediate Treatment: Discontinue Immunosuppression and Initiate Broad-Spectrum Antimicrobials

This patient presenting with fever, rash, myalgia, and facial pain while on dual immunosuppression (methotrexate and adalimumab) requires immediate discontinuation of both immunosuppressive agents and urgent evaluation for serious infection, particularly opportunistic infections including disseminated fungal disease, atypical mycobacterial infection, or reactivated tuberculosis.

Clinical Reasoning and Immediate Actions

The constellation of fever, rash, myalgia, and facial pain in a patient on combined TNF-inhibitor and methotrexate therapy is highly concerning for:

• Serious opportunistic infection (most likely)
• Drug-induced hypersensitivity syndrome
• Methotrexate toxicity with superimposed infection
• Reactivation of latent tuberculosis or fungal infection

Step 1: Discontinue All Immunosuppression Immediately

Both methotrexate and adalimumab must be stopped immediately 1. The FDA label for adalimumab explicitly warns about increased risk of serious infections with TNF-blocker therapy 2, and guidelines recommend stopping methotrexate during active infection 1.

Step 2: Urgent Diagnostic Workup

Obtain immediately:

• Blood cultures (bacterial and fungal)
• Complete blood count with differential - looking for leukopenia, thrombocytopenia suggesting bone marrow suppression or overwhelming infection
• Comprehensive metabolic panel - assess hepatic and renal function (methotrexate toxicity)
• Inflammatory markers (CRP, ESR)
• Chest radiograph - evaluate for pneumonia, tuberculosis, or fungal infection
• Urinalysis and urine culture
• Skin lesion biopsy/culture if feasible - to identify infectious etiology
• Sinus imaging if facial pain suggests sinusitis - consider invasive fungal sinusitis

Step 3: Empiric Antimicrobial Therapy

Initiate broad-spectrum antibiotics immediately while awaiting culture results:

• Vancomycin (for MRSA and resistant gram-positive coverage)
• Piperacillin-tazobactam or meropenem (for gram-negative and anaerobic coverage)
• Consider empiric antifungal therapy (voriconazole or liposomal amphotericin B) if:
  • Facial pain suggests possible invasive fungal sinusitis
  • Patient appears severely ill
  • Neutropenic or profoundly immunosuppressed

The combination of adalimumab and methotrexate creates profound immunosuppression with documented increased risk of serious infections 2, 3. Research demonstrates a two-fold increase in serious infections with adalimumab use 3, and this risk is compounded by concurrent methotrexate.

Common Pitfalls to Avoid

1. Do NOT continue immunosuppression during active infection - this is a critical error that can lead to overwhelming sepsis or death
2. Do NOT assume this is a "flare" of rheumatoid arthritis - infection must be ruled out first in immunosuppressed patients with fever
3. Do NOT delay antimicrobial therapy while waiting for definitive diagnosis - empiric treatment is essential
4. Do NOT overlook atypical/opportunistic pathogens - consider tuberculosis, Pneumocystis, Nocardia, Aspergillus, Cryptococcus, endemic fungi (Histoplasma, Coccidioides)

When to Resume Immunosuppression

Methotrexate and adalimumab should only be restarted after:

• Complete resolution of infection (documented by clinical improvement and negative cultures)
• Completion of appropriate antimicrobial course
• Normalization of inflammatory markers
• Consultation with infectious disease specialist

Guidelines support continuing methotrexate in stable patients 1, but active infection is an absolute contraindication requiring immediate cessation 1.

Special Considerations

Facial pain with fever in an immunosuppressed patient raises particular concern for:

• Invasive fungal sinusitis (Mucormycosis, Aspergillosis) - requires urgent ENT consultation and imaging
• Bacterial sinusitis with intracranial extension
• Dental abscess with facial cellulitis

If facial pain is severe or associated with visual changes, nasal necrosis, or cranial nerve deficits, obtain urgent CT or MRI of sinuses/brain and immediate ENT/neurosurgery consultation as invasive fungal sinusitis can be rapidly fatal without surgical debridement.

The evidence consistently demonstrates that TNF-inhibitors like adalimumab significantly increase infection risk 2, 3, with tuberculosis reactivation being particularly notable 3. Combined with methotrexate, this creates a high-risk scenario requiring aggressive infection management before any consideration of resuming immunosuppression.